Trial Profile
A Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With the Anti-CD33 Antibody BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs BI 836858 (Primary) ; F16 IL2 fusion protein (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms PHIBI
- Sponsors Philogen
- 13 Apr 2022 Status changed from recruiting to completed.
- 04 Jul 2017 New trial record